Dyne Therapeutics Inc. Common Stock vs Stanley Black & Decker, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Stanley Black & Decker, Inc. trades at $89.91 (market cap $13.70B). The key difference: Stanley Black & Decker, Inc. is far larger — about 4.8× Dyne Therapeutics Inc. Common Stock's market cap, and Stanley Black & Decker, Inc. pays a 3.7% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| DYN | SWK | |
|---|---|---|
Market Cap | $2.86B | $13.70B |
Volume | 3,341,579 | 1,098,669 |
Sector | Health | Industrials |
52-Week High | $26.78 | $104.00 |
52-Week Low | $14.60 | $62.12 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $2.18B | $17.86B |
Dividend Yield | — | 3.7% |
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Stanley Black & Decker (SWK) trades at $90.29, up 1.85% today, with a bearish technical signal from moving averages despite recent earnings beats. The company shows improving profitability with a net income margin of 4.07% in 2025, and revenue is projected to grow to $15.2B in 2026. Recent news highlights product launches like the dustbuster mini and management's focus on margin gains and brand strength.
The outlook is cautiously optimistic with a consensus price target of $93.00, offering modest upside. Key risks include competitive pressures and execution challenges, but strong institutional buying and a dividend history support long-term value. Investors should weigh improving fundamentals against near-term technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →